Precision BioSciences, Inc.

Clinical trials sponsored by Precision BioSciences, Inc., explained in plain language.

Precision BioSciences, Inc. DTIL NASDAQ

A clinical-stage biotech developing gene editing therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Gene therapy takes on hepatitis b: first human trial launches Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1

Gene editing for hepatitis b: researchers track Long-Term safety

Disease control By invitation only

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…

Sponsor: Precision BioSciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

Precision BioSciences, Inc.

Upcoming readouts

Gene editing for hepatitis b: researchers track Long-Term safety